Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR35579808

— · C

eac4f6a2-cc5f-5969-9952-8681087c0c9f

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
C
subtype
C

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • E2F_TARGETS+0.480
  • MYC_TARGETS_V2+0.480
  • G2M_CHECKPOINT+0.440
  • MYC_TARGETS_V1+0.370
  • OXIDATIVE_PHOSPHORYLATION+0.290
  • CHOLESTEROL_HOMEOSTASIS+0.220
  • SPERMATOGENESIS+0.210
  • ADIPOGENESIS+0.200
  • PEROXISOME+0.200
  • MITOTIC_SPINDLE+0.180

Top 10 suppressed

  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.520
  • ANGIOGENESIS-0.510
  • IL6_JAK_STAT3_SIGNALING-0.400
  • INFLAMMATORY_RESPONSE-0.400
  • TNFA_SIGNALING_VIA_NFKB-0.400
  • ALLOGRAFT_REJECTION-0.380
  • INTERFERON_GAMMA_RESPONSE-0.370
  • PANCREAS_BETA_CELLS-0.370
  • COMPLEMENT-0.320
  • HEDGEHOG_SIGNALING-0.310

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-77-8143-01A-11R-2247-07
lung-landscapes@6
—cohortSQ10.927
2SRR8518295
breast-umap@18
—E0.911
3ERR2208894
melanoma-umap@29
——0.908
4a8ce7460-8ccd-4638-a854-55c4068af6ec
colon-landscapes@1
——0.900
5TCGA-2F-A9KP-01A-11R-A38B-07
bladder-landscape@3
——0.898
6f8d9864e-e148-4e60-9d9d-3df2897050cd
colon-landscapes@1
——0.892
7fea46737-a2b3-49d4-8358-d0737546b6da
colon-landscapes@1
——0.891
8bbeadeec-bb57-4762-8828-3bd1696748fb
colon-landscapes@1
——0.891
9C3N-03882
lung-landscapes@6
—cohortSQ20.889
10513fb61a-1339-45d2-8963-6337e3aff5df
colon-landscapes@1
——0.888

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 19 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
E2F_TARGETS0.480Inavolisib— uncovered
MYC_TARGETS_V20.480Idelalisib— uncovered
G2M_CHECKPOINT0.440Inavolisib— uncovered
MYC_TARGETS_V10.370Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.290Remibrutinib— uncovered
CHOLESTEROL_HOMEOSTASIS0.220Remibrutinib— uncovered
SPERMATOGENESIS0.210Inavolisib— uncovered
ADIPOGENESIS0.200Inavolisib— uncovered
PEROXISOME0.200Idelalisib— uncovered
MITOTIC_SPINDLE0.180Inavolisib— uncovered
FATTY_ACID_METABOLISM0.170Inavolisib— uncovered
MTORC1_SIGNALING0.170Inavolisib— uncovered
NOTCH_SIGNALING0.170Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.170Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.160Idelalisib— uncovered
DNA_REPAIR0.090Idelalisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.040Inavolisib— uncovered
BILE_ACID_METABOLISM0.020Inavolisib— uncovered
KRAS_SIGNALING_DN0.010Remibrutinib— uncovered